Ad Campaign Fuels Debate On Breast-Cancer Gene Test
By Marilyn Chase,
Wall Street Journal
| 09. 11. 2007
A new direct-to-consumer ad campaign for a breast-cancer gene test is reigniting a debate over who really needs the test and whether it will induce low-risk women to take drastic measures to prevent the disease.
At issue is a series of ads to promote Myriad Genetics Inc.'s test for so-called BRCA 1 and BRCA 2 gene mutations. The mutations, while rare, signal a high risk of developing breast or ovarian cancer in affected women. Women who find they carry the mutations often take steps to lessen their risk. That can mean more frequent screenings and taking certain preventive drugs, but also can include prophylactic surgical removal of a woman's breasts or ovaries.
The gene tests aren't foolproof, however. And some experts worry that a campaign calling attention to a rare condition could create unnecessary fear -- sending thousands of healthy women with no family history of cancer into the doctor's office demanding tests that won't help them. Or lead others to a false sense of security about their results.
"Marketing has the capacity to raise public awareness -- a good...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
